Market Cap 930.47M
Revenue (ttm) 0.00
Net Income (ttm) -38.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.38
Volume 786,800
Avg Vol 1,616,012
Day's Range N/A - N/A
Shares Out 76.52M
Stochastic %K 80%
Beta -0.51
Analysts Strong Sell
Price Target $20.88

Company Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic,...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 916 5445
Address:
117 Kendrick Street, Suite 450, Needham, United States
istricky
istricky Aug. 19 at 11:26 AM
$CADL lets get an mrna day soon
1 · Reply
Kingjake26
Kingjake26 Aug. 19 at 11:20 AM
$CADL let’s post great DD. Who cares about shorts if the management team does there job they all will be smoked. Good morning too all
0 · Reply
Musky49
Musky49 Aug. 19 at 10:36 AM
$CADL Three days to options day. Will the $13.00’s be in play or the $12’s be defended? The battle begins today. KWYO 👊
0 · Reply
mau7
mau7 Aug. 19 at 10:12 AM
$CADL will shorts try to push this down today because of market sentiment? BTD time 🔥🔥🔥
1 · Reply
CharlesLazewski381
CharlesLazewski381 Aug. 19 at 9:13 AM
$TLRY $BABA $CADL $ABCL Tilray remains tied to cannabis-market conditions, Alibaba benefits from Chinese e-commerce and cloud demand, Candel Therapeutics advances cancer immunotherapies, and AbCellera supports antibody-drug discovery. I'm watching cannabis regulation, Chinese consumption, clinical milestones, partnerships, and funding.
0 · Reply
PaulNipkow
PaulNipkow Aug. 19 at 7:14 AM
$CADL not the BLA but I mean the PDUFA
1 · Reply
MurielArmstrong579
MurielArmstrong579 Aug. 19 at 7:07 AM
$TLRY $BABA $CADL $ABCL Tilray remains tied to cannabis-market conditions, Alibaba benefits from Chinese e-commerce and cloud demand, Candel Therapeutics advances cancer immunotherapies, and AbCellera supports antibody-drug discovery. I'm watching cannabis regulation, Chinese consumption, clinical milestones, partnerships, and funding.
0 · Reply
PaulNipkow
PaulNipkow Aug. 19 at 6:32 AM
$CADL $PYPD With interest rates skyrocketing, the Trump administration will hit the debt ceiling sooner than planned—perhaps as early as early 2027. Hopefully, PYPD could have already cleared it by then ; for CADL, this could affect the FDA / BLA timeline in the event of a shutdown.
2 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Aug. 19 at 3:13 AM
$CADL Might sound simple, but this is huge ---> " Dr. Barone said the company has frequent Type B meetings with the FDA under its RMAT designation, with a 60-day turnaround. She said those interactions have helped Candel align on the comparability protocol and other steps needed for the filing."
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Aug. 19 at 3:12 AM
$CADL Biologics license application filing for aglatimagene in prostate cancer by the end of 2026. The company said the manufacturing program is about three-quarters complete. --Process performance qualification campaign: about 75% complete --Commercial production scale: successfully scaled to 200-liter manufacturing --Comparability protocol: aligned with the FDA and set to be executed at the end of the PPQ campaign --Stability studies: ongoing to support shelf-life at launch --Module 3 regulatory package: being assembled for the BLA submission
1 · Reply
Latest News on CADL
Candel Therapeutics Earnings release: Q2 2026

Aug 13, 2026, 8:00 AM EDT - 5 days ago

Candel Therapeutics Earnings release: Q2 2026


Candel Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 8:00 AM EDT - 5 days ago

Candel Therapeutics Quarterly report: Q2 2026


Candel Therapeutics initiated with a Buy at Stifel

2026-07-13T09:40:23.000Z - 5 weeks ago

Candel Therapeutics initiated with a Buy at Stifel


Candel Therapeutics Slides: Corporate presentation

Jul 7, 2026, 7:00 AM EDT - 6 weeks ago

Candel Therapeutics Slides: Corporate presentation


Candel Therapeutics Transcript: AGM 2026

Jun 23, 2026, 10:00 AM EDT - 2 months ago

Candel Therapeutics Transcript: AGM 2026


Candel Therapeutics price target raised to $9 from $7 at BofA

2026-05-18T19:30:09.000Z - 3 months ago

Candel Therapeutics price target raised to $9 from $7 at BofA


Candel Therapeutics Transcript: Study result

May 15, 2026, 1:00 PM EDT - 3 months ago

Candel Therapeutics Transcript: Study result


Candel Therapeutics Slides: Study result

May 15, 2026, 1:00 PM EDT - 3 months ago

Candel Therapeutics Slides: Study result


Candel Therapeutics Press release: Study result

May 15, 2026, 1:00 PM EDT - 3 months ago

Candel Therapeutics Press release: Study result


Candel Therapeutics Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 3 months ago

Candel Therapeutics Earnings release: Q1 2026


Candel Therapeutics Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 3 months ago

Candel Therapeutics Quarterly report: Q1 2026


Candel Therapeutics Slides: Corporate presentation

May 14, 2026, 7:00 AM EDT - 3 months ago

Candel Therapeutics Slides: Corporate presentation


Candel Therapeutics to Present at Upcoming Investor Conferences

May 13, 2026, 8:05 AM EDT - 3 months ago

Candel Therapeutics to Present at Upcoming Investor Conferences


Candel Therapeutics Slides: Corporate presentation

May 13, 2026, 7:00 AM EDT - 3 months ago

Candel Therapeutics Slides: Corporate presentation


Candel Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Candel Therapeutics Proxy statement: Proxy filing


Candel Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Candel Therapeutics Proxy statement: Proxy filing


Candel Therapeutics Slides: Corporate presentation

Apr 14, 2026, 7:00 AM EDT - 4 months ago

Candel Therapeutics Slides: Corporate presentation


Candel Therapeutics price target raised to $26 from $22 at Citi

2026-03-18T10:22:07.000Z - 5 months ago

Candel Therapeutics price target raised to $26 from $22 at Citi


Candel Therapeutics Slides: Corporate presentation

Mar 17, 2026, 7:00 AM EDT - 5 months ago

Candel Therapeutics Slides: Corporate presentation


Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year

2026-03-12T12:11:41.000Z - 5 months ago

Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year


Candel Therapeutics sees cash runway into 1Q28

2026-03-12T12:11:01.000Z - 5 months ago

Candel Therapeutics sees cash runway into 1Q28


Candel Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 5 months ago

Candel Therapeutics Earnings release: Q4 2025


Candel Therapeutics Annual report: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 5 months ago

Candel Therapeutics Annual report: Q4 2025


Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

2026-02-20T03:25:29.000Z - 6 months ago

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45


Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

2026-02-20T03:25:12.000Z - 6 months ago

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45


Candel Therapeutics Announces Pricing of Public Offering

Feb 19, 2026, 9:40 PM EST - 6 months ago

Candel Therapeutics Announces Pricing of Public Offering


Candel Therapeutics announces $100M royalty funding agreement

2026-02-19T22:10:17.000Z - 6 months ago

Candel Therapeutics announces $100M royalty funding agreement


Candel Therapeutics announces $100M common stock offering

2026-02-19T21:13:42.000Z - 6 months ago

Candel Therapeutics announces $100M common stock offering


Candel Therapeutics Slides: Corporate Presentation

Dec 10, 2025, 7:00 AM EST - 8 months ago

Candel Therapeutics Slides: Corporate Presentation


Candel Therapeutics Transcript: R&D Day 2025

Dec 5, 2025, 11:00 AM EST - 9 months ago

Candel Therapeutics Transcript: R&D Day 2025


Candel Therapeutics Press release: FY 2025

Dec 5, 2025, 11:00 AM EST - 9 months ago

Candel Therapeutics Press release: FY 2025


Candel Therapeutics reports Q3 EPS (21c) vs (33c) last year

2025-11-13T13:31:40.000Z - 9 months ago

Candel Therapeutics reports Q3 EPS (21c) vs (33c) last year


Candel Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

Candel Therapeutics Quarterly report: Q3 2025


Candel Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

Candel Therapeutics Earnings release: Q3 2025


Candel Therapeutics Slides: Corporate Presentation

Nov 12, 2025, 7:00 AM EST - 9 months ago

Candel Therapeutics Slides: Corporate Presentation


Candel Therapeutics initiated with an Overweight at Stephens

2025-10-27T20:35:14.000Z - 10 months ago

Candel Therapeutics initiated with an Overweight at Stephens


Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Oct 3, 2025, 9:05 AM EDT - 11 months ago

Candel Therapeutics to Present at the SITC 2025 Annual Meeting


Candel Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Quarterly report: Q2 2025


Candel Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Earnings release: Q2 2025


Candel Therapeutics Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Quarterly report: Q1 2025


Candel Therapeutics Earnings release: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Earnings release: Q1 2025


Candel Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Proxy statement: Proxy Filing


Candel Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Proxy statement: Proxy Filing


istricky
istricky Aug. 19 at 11:26 AM
$CADL lets get an mrna day soon
1 · Reply
Kingjake26
Kingjake26 Aug. 19 at 11:20 AM
$CADL let’s post great DD. Who cares about shorts if the management team does there job they all will be smoked. Good morning too all
0 · Reply
Musky49
Musky49 Aug. 19 at 10:36 AM
$CADL Three days to options day. Will the $13.00’s be in play or the $12’s be defended? The battle begins today. KWYO 👊
0 · Reply
mau7
mau7 Aug. 19 at 10:12 AM
$CADL will shorts try to push this down today because of market sentiment? BTD time 🔥🔥🔥
1 · Reply
CharlesLazewski381
CharlesLazewski381 Aug. 19 at 9:13 AM
$TLRY $BABA $CADL $ABCL Tilray remains tied to cannabis-market conditions, Alibaba benefits from Chinese e-commerce and cloud demand, Candel Therapeutics advances cancer immunotherapies, and AbCellera supports antibody-drug discovery. I'm watching cannabis regulation, Chinese consumption, clinical milestones, partnerships, and funding.
0 · Reply
PaulNipkow
PaulNipkow Aug. 19 at 7:14 AM
$CADL not the BLA but I mean the PDUFA
1 · Reply
MurielArmstrong579
MurielArmstrong579 Aug. 19 at 7:07 AM
$TLRY $BABA $CADL $ABCL Tilray remains tied to cannabis-market conditions, Alibaba benefits from Chinese e-commerce and cloud demand, Candel Therapeutics advances cancer immunotherapies, and AbCellera supports antibody-drug discovery. I'm watching cannabis regulation, Chinese consumption, clinical milestones, partnerships, and funding.
0 · Reply
PaulNipkow
PaulNipkow Aug. 19 at 6:32 AM
$CADL $PYPD With interest rates skyrocketing, the Trump administration will hit the debt ceiling sooner than planned—perhaps as early as early 2027. Hopefully, PYPD could have already cleared it by then ; for CADL, this could affect the FDA / BLA timeline in the event of a shutdown.
2 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Aug. 19 at 3:13 AM
$CADL Might sound simple, but this is huge ---> " Dr. Barone said the company has frequent Type B meetings with the FDA under its RMAT designation, with a 60-day turnaround. She said those interactions have helped Candel align on the comparability protocol and other steps needed for the filing."
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Aug. 19 at 3:12 AM
$CADL Biologics license application filing for aglatimagene in prostate cancer by the end of 2026. The company said the manufacturing program is about three-quarters complete. --Process performance qualification campaign: about 75% complete --Commercial production scale: successfully scaled to 200-liter manufacturing --Comparability protocol: aligned with the FDA and set to be executed at the end of the PPQ campaign --Stability studies: ongoing to support shelf-life at launch --Module 3 regulatory package: being assembled for the BLA submission
1 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Aug. 19 at 3:11 AM
$CADL The company plans to present more prostate cancer data at ASTRO 2026 in September. That presentation is expected to include: AI-enabled digital pathology analysis of 2-year post-treatment biopsies Histological parameters such as immune cell aggregates and their distribution Measures of immune cell proximity to cancer cells Additional mechanistic insight into how the therapy works
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Aug. 19 at 3:10 AM
$CADL Sep 29, ASTRO is going to be awesome imho...
0 · Reply
Atomickb
Atomickb Aug. 19 at 2:36 AM
$CADL - someone alreadt covered from 16 to 12 million. More covering as price has clinbed to 12. Wont be suprised to see short interest down again. The recent fair calue report should prompt more buying and covering. Its slow so that price does not movr much. Someone will cover / buy big. Should get a rally to 16-18 quickly.
2 · Reply
Horsecock_the_Grey
Horsecock_the_Grey Aug. 19 at 12:39 AM
$CADL Tell it near and far
4 · Reply
CargoShorts4Life
CargoShorts4Life Aug. 18 at 11:08 PM
$CADL I’m really sad I dumped 45k shares around $6 to chase another ticker. Congrats Jake and all.
2 · Reply
Newageinvestor
Newageinvestor Aug. 18 at 10:42 PM
$CADL How did we do. 18 month opening high ($11.92) and intraday low ($11.77). Next highest low was yesterdays $11.11 so it wa la the highest low by a lot. Intraday high ($12.15) and close ($12.05) were number two for the 18month high. Volume was light as previously mentioned. With the normal end of day volume spike and it occurred on the upside today. Overall a solid basing day. The trend continues!
0 · Reply
Newageinvestor
Newageinvestor Aug. 18 at 10:26 PM
$CADL From around 12:45pm EST to 3:15 EST the stock traded around 167k shares (320k to 487k), or approximately 34k shares every half hour period. Then , In the final 45min of the trading day, the stock traded approximately 300k (487k to 787k) shares the equivalent of 200k shares every half hour period. So while the overall volume was relatively low, the typical end of day volume spike was in sync with the recent trading environment. The stock closed on the upside of $12 having traded below $12 for a majority of the day. As a result, a high percentage of the trades were executed over $12 a share.
1 · Reply
claybridge
claybridge Aug. 18 at 8:48 PM
$CADL since the series B warrants came up today and we're approaching the price that the 1st tranche can be executed, I thought I'd put this here (from the 10-Q). I expect all tranches to be executed by EOY, which will bring in $25M.
4 · Reply
moneymaker444
moneymaker444 Aug. 18 at 8:11 PM
$CADL From King 🤴 Accumulation zone...the twilight zone episode 4... 5.88...8.08...9.71 .. Now 11.80 episode 4 twilight zone.... It's a Good Life" (Season 3, Episode 3) is widely considered the most disturbing Twilight Zone episode. It features a terrifying 6-year-old boy named Anthony who holds total god-like control over a helpless, isolated town. Anyone who displeases him is brutally wished away or mutated into a monster. .. enjoy... machine was on all day...
3 · Reply
marked0ne
marked0ne Aug. 18 at 8:05 PM
$CADL more than 1/4 of todays shares were traded in the last 10 minutes (200k out of 786k). The pattern continous. Let that sink in…..
1 · Reply
CapitalMonk
CapitalMonk Aug. 18 at 7:50 PM
$CADL Price: $11.96 (-1.64%) Trend: Bullish Market Bias (7D): Bullish Bias 📈 Expected Range: ±8.26% RSI: 87.6 | Momentum: Strong Momentum Volume: -52.2% vs avg Volatility: 3.35% Support: $9.16 | Resistance: $12.48 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
0 · Reply
Drcando
Drcando Aug. 18 at 7:46 PM
$CADL Piss poor volume Very little float That's great Institutions will continue to increase their stake an we will see the Lemonade Stand opening KWYO ‼️‼️‼️
0 · Reply